These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 24530100

  • 21. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
    Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, Yoshikawa J, Ito H.
    Cardiovasc Diabetol; 2014 Jul 30; 13():110. PubMed ID: 25074318
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group.
    Diabetes Care; 2006 Dec 30; 29(12):2638-43. PubMed ID: 17130197
    [Abstract] [Full Text] [Related]

  • 25. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N.
    Expert Opin Investig Drugs; 2008 Jun 30; 17(6):845-53. PubMed ID: 18491986
    [Abstract] [Full Text] [Related]

  • 26. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.
    Nomiyama T, Akehi Y, Takenoshita H, Nagaishi R, Terawaki Y, Nagasako H, Kudo T, Kodera T, Kobayashi K, Urata H, Yanase T, CHAT.
    Diabetes Res Clin Pract; 2012 Feb 30; 95(2):e27-8. PubMed ID: 21899912
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
    Kanazu S, Horie Y, Narukawa M, Nonaka K, Taniguchi T, Arjona Ferreira JC, Takeuchi M.
    Diabetes Obes Metab; 2009 Aug 30; 11(8):813-8. PubMed ID: 19476471
    [Abstract] [Full Text] [Related]

  • 29. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
    Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K.
    Cardiovasc Diabetol; 2012 Aug 06; 11():92. PubMed ID: 22867630
    [Abstract] [Full Text] [Related]

  • 30. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H, Miwa T, Kan K, Matsuhisa M, Kamiya H, Nanasato M, Kitano T, Sano H, Ohno J, Iida M, Sata M, Yamada H, Maemura K, Tanaka A, Murohara T, Node K.
    Cardiovasc Diabetol; 2016 Nov 03; 15(1):150. PubMed ID: 27809848
    [Abstract] [Full Text] [Related]

  • 31. Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
    Shima K, Komatsu M, Noma Y, Miya K.
    Intern Med; 2014 Nov 03; 53(8):829-35. PubMed ID: 24739602
    [Abstract] [Full Text] [Related]

  • 32. Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
    Maeda H, Kubota A, Kanamori A, Tanaka Y, Terauchi Y, Matsuba I, ASSET-K Study Group.
    J Endocrinol Invest; 2013 Sep 03; 36(8):568-73. PubMed ID: 23385888
    [Abstract] [Full Text] [Related]

  • 33. Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
    Arai K, Maeda H, Shirabe S, Yamamoto R, Kumakura A, Yamauchi M, Hirao T, Hirao S, Hirao K.
    Diabetes Technol Ther; 2014 Jul 03; 16(7):442-6. PubMed ID: 24528246
    [Abstract] [Full Text] [Related]

  • 34. Effects of sitagliptin beyond glycemic control: focus on quality of life.
    Sakamoto Y, Oyama J, Ikeda H, Kuroki S, Gondo S, Iwamoto T, Uchida Y, Kodama K, Hiwatashi A, Shimomura M, Taguchi I, Inoue T, Node K, S-DOG investigators.
    Cardiovasc Diabetol; 2013 Feb 21; 12():35. PubMed ID: 23432786
    [Abstract] [Full Text] [Related]

  • 35. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study.
    Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, Hirata A, Nakagawa Y, Kashine S, Oka A, Hayashi M, Nishizawa H, Funahashi T, Shimomura I.
    Cardiovasc Diabetol; 2014 May 24; 13():96. PubMed ID: 24884787
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC, Chien KL, Wang CH, Chen WC, Leung CH.
    Endocr Pract; 2013 May 24; 19(6):980-8. PubMed ID: 23807528
    [Abstract] [Full Text] [Related]

  • 37. [Type 2 diabetes: interview with Prof. Stephan Matthaei. Reaching HbA1c target value while preventing hypoglycemia].
    Matthaei S.
    MMW Fortschr Med; 2009 Oct 15; 151(42):54. PubMed ID: 19938786
    [No Abstract] [Full Text] [Related]

  • 38. Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.
    Öz Ö, Kıyıcı S, Ersoy C, Cander S, Yorulmaz H, Gül CB, Ünal OK, Sarandol E, Kırhan E, Sığırlı D, Ertürk E, Tuncel E, Imamoğlu S.
    Diabetes Res Clin Pract; 2011 Nov 15; 94(2):212-6. PubMed ID: 21855160
    [Abstract] [Full Text] [Related]

  • 39. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.
    Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S.
    Tohoku J Exp Med; 2011 Feb 15; 223(2):133-5. PubMed ID: 21304217
    [Abstract] [Full Text] [Related]

  • 40. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE, Bhosekar V, Kawamori R.
    Vasc Health Risk Manag; 2016 Feb 15; 12():9-12. PubMed ID: 26855580
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.